Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oncolytics Biotech stock

Learn how to easily invest in Oncolytics Biotech stock.

Oncolytics Biotech Inc is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Oncolytics Biotech employs 26 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Oncolytics Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Oncolytics Biotech stock price (NASDAQ: ONCY)

Use our graph to track the performance of ONCY stocks over time.

Oncolytics Biotech shares at a glance

Information last updated 2022-09-26.
Latest market close$1.23
52-week range$0.80 - $2.38
50-day moving average $1.26
200-day moving average $1.39
Wall St. target price$10.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.37

Buy Oncolytics Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oncolytics Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncolytics Biotech price performance over time

Historical closes compared with the close of $1.23 from 2022-09-30

1 week (2022-09-23) -1.60%
1 month (2022-09-01) -10.22%
3 months (2022-07-01) 24.24%
6 months (2022-03-30) -22.64%
1 year (2021-09-27) -43.32%
2 years (2020-10-01) -28.07%
3 years (2019-10-01) 137.41%
5 years (2017-09-29) 135.23%

Oncolytics Biotech financials

Gross profit TTM $0
Return on assets TTM -33.62%
Return on equity TTM -63.41%
Profit margin 0%
Book value $0.53
Market capitalisation $71.7 million

TTM: trailing 12 months

Oncolytics Biotech share dividends

We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.

Have Oncolytics Biotech's shares ever split?

Oncolytics Biotech's shares were split on a 10:95 basis on 25 May 2018. So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.

Oncolytics Biotech share price volatility

Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.8 up to $2.38. A popular way to gauge a stock's volatility is its "beta".

ONCY.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.6692. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncolytics Biotech overview

Oncolytics Biotech Inc. , a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Frequently asked questions

What percentage of Oncolytics Biotech is owned by insiders or institutions?
Currently 1.32% of Oncolytics Biotech shares are held by insiders and 1.685% by institutions.
How many people work for Oncolytics Biotech?
Latest data suggests 26 work at Oncolytics Biotech.
When does the fiscal year end for Oncolytics Biotech?
Oncolytics Biotech's fiscal year ends in December.
Where is Oncolytics Biotech based?
Oncolytics Biotech's address is: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5
What is Oncolytics Biotech's ISIN number?
Oncolytics Biotech's international securities identification number is: CA6823108759
What is Oncolytics Biotech's CUSIP number?
Oncolytics Biotech's Committee on Uniform Securities Identification Procedures number is: 682310875

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site